Modeled Economic Evaluation of Alternative Strategies to Reduce Sudden Cardiac Death Among Children Treated for Attention Deficit/Hyperactivity Disorder

Plain English Summary

Summary written for general audiences

Researchers analyzed whether adding ECG screening to routine checkups could prevent sudden cardiac death in children prescribed ADHD stimulant medications. They found that ECG screening would prevent 13 deaths per 400,000 children treated, but at a high cost of $1.2-1.6 million per life saved. The screening showed borderline cost-effectiveness compared to current standard care.

Why This Matters

While this study doesn't directly examine EMF exposure, it highlights a critical gap in how we assess health risks for children. The researchers found that even expensive cardiac screening for stimulant medications barely meets cost-effectiveness thresholds, preventing just 13 deaths per 400,000 children treated. This raises important questions about our priorities in pediatric health protection. We routinely spend billions on pharmaceutical interventions with marginal benefits, yet we largely ignore the growing body of research showing EMF exposure effects on developing brains and bodies. Children today face unprecedented wireless radiation exposure from phones, tablets, WiFi, and cellular networks - exposure that didn't exist when safety standards were set decades ago. If we're willing to consider costly screening for rare cardiac events, shouldn't we also be taking seriously the mounting evidence of EMF health effects that could impact far more children?

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study

Peter Denchev, Jonathan R. Kaltman, Michael Schoenbaum, Benedetto Vitiello (2010). Modeled Economic Evaluation of Alternative Strategies to Reduce Sudden Cardiac Death Among Children Treated for Attention Deficit/Hyperactivity Disorder.

Show BibTeX

@article{modeled_economic_evaluation_of_alternative_strategies_to_reduce_sudden_cardiac_d_g7307,
  author = {Peter Denchev and Jonathan R. Kaltman and Michael Schoenbaum and Benedetto Vitiello},
  title = {Modeled Economic Evaluation of Alternative Strategies to Reduce Sudden Cardiac Death Among Children Treated for Attention Deficit/Hyperactivity Disorder},
  year = {2010},
  
  
}

Quick Questions About This Study

The study found that ECG screening would prevent 13 sudden cardiac deaths per 400,000 children seeking stimulant treatment for ADHD, making it a relatively rare but serious risk that screening could help identify.

ECG screening costs between $1.2-1.6 million per life saved when added to standard physical exams before prescribing ADHD stimulant medications, making it expensive but potentially worthwhile prevention.

The screening showed borderline cost-effectiveness at $27,200-39,300 per quality-adjusted life-year, with a 71% chance of being cost-effective under standard healthcare spending thresholds of $50,000 per life-year.

The researchers modeled children ages 7 to 17 years old who were candidates for stimulant medication treatment, using 10 annual cycles to track long-term health outcomes and costs.

The study found that most benefits from ECG screening came from restricting children with identified cardiac risks from competitive sports, not just from avoiding stimulant medications alone.